Erratum

No keyword matches — expanded with semantic search

community Mildly Interesting: Kintor removes the annotation that pictures are from clinical experiments and that KX-826 gives "real" visible results, editing their Amazon page once again

in Product  24 upvotes 1 year ago

Kintor edited their Amazon page, removing claims that KX-826 provides "real" visible results from clinical experiments. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

community PP405 (Non) Update - Feb 2025

in Research/Science  34 upvotes 1 year ago

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

community Does anyone have the removed Breezula phase II 12 month baseline comparison results?

in Research/Science  8 upvotes 5 years ago

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

community Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)

in Chat  12 upvotes 1 year ago

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

community Trial for TDM-105795 update from research office

in Research/Science  16 upvotes 2 years ago

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

community PP405 2a study was a safety study. Some rational explaining.

in Research/Science  22 upvotes 6 months ago

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.